Biomea Fusion, Inc.

BMEA

US09077A1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:20:41 2024-04-26 am EDT			5-day change	1st Jan Change
10.5 ^USD	+0.29%		-2.58%	-27.20%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Apr. 02	Biomea Fusion Shares Decline Following JPMorgan Downgrade	MT

Biomea Fusion, Inc.(NasdaqGS:BMEA) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Biomea Fusion, Inc.

North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Biomea Fusion Shares Decline Following JPMorgan Downgrade	Apr. 02	MT
JPMorgan Downgrades Biomea Fusion to Neutral From Overweight, Adjusts Price Target to $14 From $51	Apr. 02	MT
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)	Apr. 01	CI
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	Mar. 06	CI
Truist Securities Starts Biomea Fusion With Buy Rating, $55 Price Target	Feb. 06	MT
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219	Jan. 08	CI
Biomea Fusion, Inc. Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts	Dec. 09	CI
Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes	Dec. 08	CI
Biomea Fusion Says Long-Term Data Show Improved Glycemic Control in Phase 2 Trial of BMF-219 to Treat Diabetes	Dec. 08	MT
Biomea Fusion's Ongoing Phase 2 Study of BMF-219 Shows Glycated Hemoglobin Reductions in Patients With Type 2 Diabetes	Dec. 07	MT
Biomea Fusion Receives Health Canada Clearance for Phase 2 Trial of BMF-219 in Type 1 Diabetes	Dec. 05	MT
Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application for BMF-219 in Type 1 Diabetes	Dec. 05	CI
Biomea Fusion Surges Nearly 20% Premarket Wednesday	Nov. 29	MT
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease	Nov. 08	CI
Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023	Nov. 02	CI
Biomea Fusion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)	23-10-17	CI
Biomea Fusion Investigational New Drug Application for Diabetes Candidate Approved by FDA	23-10-05	MT
Biomea Fusion Gets FDA, Health Canada Clearance for Expansion Groups in Mid-Stage Diabetes Study	23-09-28	MT
Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study	23-09-28	CI
Biomea Fusion Names Juan Pablo Frias as Chief Medical Officer, Steve Morris to Become Chief Development Officer	23-08-31	MT
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer	23-08-31	CI

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.47 USD

Average target price

49.38 USD

Spread / Average Target

+371.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOMEA FUSION, INC.	-27.20%	376M
IQVIA HOLDINGS INC.	+1.58%	42.59B
MODERNA, INC.	+8.00%	40.65B
LONZA GROUP AG	+48.88%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.17%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.18%	18.17B
MEDPACE HOLDINGS, INC.	+28.47%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.05%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.55%	11.1B

Other Biotechnology & Medical Research